Literature DB >> 10418924

Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid.

H Ahman1, H Käyhty, A Vuorela, O Leroy, J Eskola.   

Abstract

Three injections of tetravalent pneumococcal polysaccharide-tetanus toxoid conjugate vaccine (PncT) were given to infants at 2, 4 and 6 months of age simultaneously with diphtheria-tetanus-pertussis and Haemophilus influenzae type b-tetanus toxoid conjugate vaccines. Three doses (1, 3 or 10 microg) of polysaccharides were used. Children were boosted with unconjugated polysaccharide vaccine at 14 months of age. No dose dependency was seen after primary immunization. However, booster response to three vaccine serotypes was highest in the group primed with the lowest dose of conjugate vaccine. As the magnitude of the response to booster may be related to the number of polysaccharide-specific memory B cells, we hypothesize that the 10 microg dose of the tetravalent conjugate vaccine is too high for optimal induction of immunologic memory.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10418924     DOI: 10.1016/s0264-410x(99)00048-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.

Authors:  F M Russell; P V Licciardi; A Balloch; V Biaukula; L Tikoduadua; J R Carapetis; J Nelson; A W J Jenney; L Waqatakirewa; S Colquhoun; Y B Cheung; M L K Tang; E K Mulholland
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

3.  Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.

Authors:  Ron Dagan; David Goldblatt; James R Maleckar; Mansour Yaïch; Juhani Eskola
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

4.  Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.

Authors:  Ray Borrow; David Goldblatt; Adam Finn; Joanna Southern; Lindsey Ashton; Nick Andrews; Gouri Lal; Christine Riley; Rukhsana Rahim; Keith Cartwright; Geraldine Allan; Elizabeth Miller
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

5.  A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.

Authors:  R Rupp; D Hurley; S Grayson; J Li; K Nolan; R D McFetridge; J Hartzel; C Abeygunawardana; M Winters; H Pujar; P Benner; L Musey
Journal:  Hum Vaccin Immunother       Date:  2019-02-15       Impact factor: 3.452

6.  Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

Authors:  Fatme Mawas; Jutta Niggemann; Christopher Jones; Michael J Corbel; Johannis P Kamerling; Johannes F G Vliegenthart
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

7.  Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.

Authors:  Do Gia Canh; Feng-ying Kimi Lin; Vu Dinh Thiem; Dang Duc Trach; Nguyen Dinh Trong; Nguyen Duc Mao; Steven Hunt; Rachel Schneerson; John B Robbins; Chiayung Chu; Joseph Shiloach; Dolores A Bryla; Marie-Claude Bonnet; Dominique Schulz; Shousun C Szu
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.609

8.  CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria.

Authors:  Georgina Bowyer; Amy Grobbelaar; Tommy Rampling; Navin Venkatraman; Danielle Morelle; Ripley W Ballou; Adrian V S Hill; Katie J Ewer
Journal:  Front Immunol       Date:  2018-07-25       Impact factor: 7.561

9.  Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults.

Authors:  Niloufar Kavian; Asmaa Hachim; Athena Py Li; Carolyn A Cohen; Alex Wh Chin; Leo Lm Poon; Vicky J Fang; Nancy Hl Leung; Benjamin J Cowling; Sophie A Valkenburg
Journal:  Clin Transl Immunology       Date:  2020-02-03

Review 10.  Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review.

Authors:  R K Lucinde; G Ong'ayo; C Houlihan; C Bottomley; D Goldblatt; J A G Scott; K E Gallagher
Journal:  Vaccine       Date:  2021-07-31       Impact factor: 4.169

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.